Rayno Life Science: DX and Tools Update ALR 5/11/12
More Bad News on Alere The second shoe has dropped on Alere (ALR $19) with the stock off 15% as the FDA inspection news regarding manufacturing and quality at the “Biosite”facility.Leerink Swann downgraded the stock to “Market Perform” after trying to support the stock...
Rayno Life Science Update-Macro Rules, Risk Off
Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only...
Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%
The NASDAQ Biotechnology Index IBB ($122.30) is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors to...
Alere Inc.(ALR) : Where is the bottom and what went wrong?
ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an opportunity to get out in the...
Rayno Life Science Portfolio Update: ALR, GPRO, REGN
Consolidation Continues in Mid Cap DX Companies: Bull Market in Biotech Hits New Highs Our Life Science Tools and Diagnostics Portfolio had a nice hit today with GenProbe up 18.75% on the Agreement that it would be sold to Hologic (HOLX $18.82 down 11.2%) for $3.7B or $82.75/sh. This is a...
